33.87
前日終値:
$33.33
開ける:
$33.58
24時間の取引高:
971.63K
Relative Volume:
0.99
時価総額:
$2.66B
収益:
$1.55M
当期純損益:
$-258.76M
株価収益率:
-8.6951
EPS:
-3.8953
ネットキャッシュフロー:
$-213.66M
1週間 パフォーマンス:
+4.50%
1か月 パフォーマンス:
+14.77%
6か月 パフォーマンス:
+23.88%
1年 パフォーマンス:
+84.38%
Celldex Therapeutics Inc Stock (CLDX) Company Profile
Compare CLDX vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
CLDX
Celldex Therapeutics Inc
|
33.87 | 2.62B | 1.55M | -258.76M | -213.66M | -3.8953 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Celldex Therapeutics Inc Stock (CLDX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-23 | アップグレード | Wolfe Research | Peer Perform → Outperform |
| 2025-10-21 | 開始されました | Mizuho | Outperform |
| 2025-10-13 | 開始されました | Barclays | Underweight |
| 2025-04-28 | 開始されました | Canaccord Genuity | Buy |
| 2025-03-20 | 開始されました | Morgan Stanley | Overweight |
| 2025-02-13 | 開始されました | UBS | Buy |
| 2024-10-07 | 開始されました | Citigroup | Buy |
| 2024-09-30 | 開始されました | Goldman | Neutral |
| 2024-09-27 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
| 2024-06-18 | 開始されました | Stifel | Buy |
| 2024-06-11 | 開始されました | Wolfe Research | Outperform |
| 2023-12-20 | 開始されました | TD Cowen | Outperform |
| 2023-11-10 | アップグレード | Wells Fargo | Underweight → Equal Weight |
| 2023-08-22 | 開始されました | Wells Fargo | Underweight |
| 2021-09-17 | 開始されました | Jefferies | Buy |
| 2021-09-10 | 開始されました | SVB Leerink | Outperform |
| 2021-07-22 | 開始されました | Guggenheim | Buy |
| 2020-02-21 | 開始されました | Cantor Fitzgerald | Overweight |
| 2017-08-01 | 再開されました | H.C. Wainwright | Buy |
| 2016-11-07 | 開始されました | Aegis Capital | Buy |
| 2016-03-08 | ダウングレード | Jefferies | Buy → Hold |
| 2016-03-07 | ダウングレード | Guggenheim | Buy → Neutral |
| 2016-03-07 | ダウングレード | Leerink Partners | Outperform → Mkt Perform |
| 2016-03-07 | ダウングレード | Wedbush | Outperform → Neutral |
| 2016-03-01 | 開始されました | H.C. Wainwright | Buy |
| 2015-08-11 | 繰り返されました | Brean Capital | Buy |
| 2015-08-11 | 繰り返されました | Oppenheimer | Outperform |
| 2015-08-11 | 繰り返されました | ROTH Capital | Buy |
| 2015-06-02 | 繰り返されました | WBB Securities | Strong Buy |
| 2014-11-17 | 繰り返されました | ROTH Capital | Buy |
| 2014-03-04 | 繰り返されました | Oppenheimer | Outperform |
| 2013-07-08 | 繰り返されました | Cantor Fitzgerald | Buy |
| 2013-03-08 | 繰り返されました | Cantor Fitzgerald | Buy |
| 2013-02-26 | 繰り返されました | Oppenheimer | Outperform |
| 2013-01-10 | 繰り返されました | Cantor Fitzgerald | Buy |
| 2012-10-02 | 繰り返されました | Oppenheimer | Outperform |
| 2012-09-14 | 繰り返されました | Cantor Fitzgerald | Buy |
すべてを表示
Celldex Therapeutics Inc (CLDX) 最新ニュース
Celldex Therapeutics Spotlights Barzolvolimab as Phase III CSU Data Looms After Fast Enrollment - Yahoo Finance
Celldex prices $300M stock at $29 per share to fuel Barzolvolimab launch - MSN
CLDX: Barzolvolimab shows strong, durable efficacy in urticaria with pivotal phase III data due Q4 - TradingView — Track All Markets
Celldex to Present at Upcoming Investor Conference - The Manila Times
Celldex Therapeutics announces public offering of common stock - MSN
A Look At Celldex Therapeutics (CLDX) Valuation After Equity Raise And New Barzolvolimab Data - Sahm
Precision Trading with Celldex Therapeutics Inc. (CLDX) Risk Zones - Stock Traders Daily
RSI Check: Why is Vistagen Therapeutics Inc stock going downBull Run & Real-Time Volume Analysis Alerts - baoquankhu1.vn
Celldex Therapeutics Closes $345M Public Stock Offering - National Today
Celldex closes $345 million stock offering By Investing.com - Investing.com Australia
Celldex Therapeutics Completes $345 Million Public Offering of Common Stock - Quiver Quantitative
Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares - marketscreener.com
Did Celldex’s (CLDX) US$300 Million Equity Raise to Fund Barzolvolimab Just Shift Its Investment Narrative? - Sahm
Celldex Therapeutics, Inc. (CLDX) Options Chain - Yahoo! Finance Canada
Ambrosia, Syneron move toward clinic with nine-digit series B rounds: Finance Report - biocentury.com
JPMorgan Chase & Co. Sells 49,046 Shares of Celldex Therapeutics, Inc. $CLDX - MarketBeat
Celldex Announces Pricing of $300 Million Public Offering of Common Stock - Sahm
Celldex Therapeutics stock falls on equity offering - Investing.com
Celldex Therapeutics stock falls on equity offering By Investing.com - ca.investing.com
Celldex prices $300 million stock offering at $29 per share By Investing.com - Investing.com Australia
Celldex Therapeutics offers 10,345,000 shares of common stockSEC filing - marketscreener.com
Celldex Therapeutics (NASDAQ: CLDX) raises ~$282M net in $29 follow-on offering - Stock Titan
Celldex Therapeutics (NASDAQ:CLDX) Sees Unusually-High Trading VolumeHere's Why - MarketBeat
Celldex shares plunge after dumping $300 million stock deal - GuruFocus
Celldex Announces Major Underwritten Public Equity Offering - TipRanks
Celldex Therapeutics Inc (TCE2.MU) Stock Price, News, Quote & History - Yahoo! Finance Canada
Celldex Therapeutics Prices $29 Share Sale, Expects $282 Million Net From Underwritten Offering - TradingView — Track All Markets
Celldex (NASDAQ: CLDX) raises $300M in new common stock sale - Stock Titan
Is Celldex’s US$300 Million Follow-On To Fund Barzolvolimab Altering The Investment Case For CLDX? - Yahoo Finance
Celldex launches public offering of common stock By Investing.com - Investing.com South Africa
Celldex Therapeutics Inc (TCE2.DU) Stock Price, News, Quote & History - ca.finance.yahoo.com
Celldex Announces $300 Million Public Stock Offering - National Today
Celldex Therapeutics Inc (CLDX) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):